Not logged in
Talk
Contributions
Create account
Log in
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Page
Discussion
Edit
Edit source
View history
Editing
Trials (The Prof. Dr. Ion Chiricuta Institute of Oncology
From Beacon
Jump to:
navigation
,
search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
<span style="display:none">forpatients</span> <span style="display:none">forresearchers</span> <span style="display:none">forproviders</span> <span style="display:none">romaniacountry</span> Go back to [[The Prof. Dr. Ion Chiricuta Institute of Oncology]] page === Trials: How to participate === '''Contact information:''' [https://iocn.ro/cercetare/#1575822510108-3b9c7f85-5bd6 Click here to access]. '''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma. '''Sponsor''': Immunocore Ltd '''Intervention''': IMC-F106C '''Start Date''': 2023-12-01 '''Last Updated''': 2023-11-01 '''Number of Patients''': 680 '''Recruitment Status''': NOT_YET_RECRUITING '''Condition''': Advanced Melanoma '''NCTID''': NCT02302807 '''Title''': A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] '''Study Summary''': This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody '''Start Date''': 2015-01-13 '''Last Updated''': 2019-08-01 '''Number of Patients''': 931 '''Recruitment Status''': COMPLETED '''Condition''': Bladder Cancer '''NCTID''': NCT00040183 '''Title''': OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. '''Study Summary''': The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer. '''Sponsor''': OSI Pharmaceuticals '''Intervention''': Tarceva (erlotinib HCl, OSI-774) '''Start Date''': 2001-11-29 '''Last Updated''': 2018-01-10 '''Number of Patients''': 569 '''Recruitment Status''': COMPLETED '''Condition''': Pancreatic Cancer '''NCTID''': NCT00806286 '''Title''': Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer '''Study Summary''': The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. The study will find out if adding CS-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in subjects with metastatic non-small cell lung cancer. '''Sponsor''': Daiichi Sankyo, Inc. '''Intervention''': CS7017 tablets '''Start Date''': 2008-12 '''Last Updated''': 2020-05-13 '''Number of Patients''': 111 '''Recruitment Status''': COMPLETED '''Condition''': Metastatic Non-small Cell Lung Cancer '''NCTID''': NCT03425643 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) '''Study Summary''': This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery <math display="block">neoadjuvant phase</math>, followed by pembrolizumab alone after surgery <math display="block">adjuvant phase</math> in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2018-04-24 '''Last Updated''': 2023-11-13 '''Number of Patients''': 797 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Non-small Cell Lung Cancer '''NCTID''': NCT05879822 '''Title''': A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive '''Study Summary''': This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. '''Sponsor''': Incyte Corporation '''Intervention''': INCB099280 '''Start Date''': 2023-10-30 '''Last Updated''': 2023-11-09 '''Number of Patients''': 314 '''Recruitment Status''': RECRUITING '''Condition''': Advanced Solid Tumor '''NCTID''': NCT04953897 '''Title''': Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment '''Study Summary''': This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 mg and cedazuridine 100 mg in cancer participants with severe renal impairment and cancer participants with normal renal function as matched control subjects. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration is approximately up to 8 weeks. '''Sponsor''': Astex Pharmaceuticals, Inc. '''Intervention''': ASTX727 '''Start Date''': 2021-12-15 '''Last Updated''': 2023-07-03 '''Number of Patients''': 18 '''Recruitment Status''': RECRUITING '''Condition''': Acute Myeloid Leukemia '''NCTID''': NCT03155997 '''Title''': Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer '''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. '''Sponsor''': Eli Lilly and Company '''Intervention''': Abemaciclib '''Start Date''': 2017-07-12 '''Last Updated''': 2023-07-14 '''Number of Patients''': 5637 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Breast Cancer '''NCTID''': NCT05947903 '''Title''': Validation of the European Oncology Quality of Life Toolkit '''Study Summary''': The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship, and advanced terminal stages. Clinical studies and real-world data show that the use of Patient Reported Outcome Measures (PROMs) for QoL assessment in routine oncology practice has positive effects on patient wellbeing and healthcare resource utilization. However, full implementation of PROMs is not yet part of standard of care and is not adequately considered in cancer policies and programs. A comprehensive tool incorporating the perspective of patients at different stages of the disease trajectory and widely applicable across Europe is still lacking. The European Oncology Quality of Life Toolkit (EUonQoL-Kit) is a unified patient-centred tool for the assessment of QoL, developed from preferences and priorities of people with past or current cancer experience. The EUonQoL-Kit includes three electronic questionnaires, specifically designed for different disease phases (patients in active treatment, survivors, and patients in palliative care), available in both static and dynamic (Computer Adaptive Testing, CAT) versions and in several European languages. This is a multicentre observational study, with the following aims: * The primary aim is to perform the psychometric validation of the EUonQoL-Kit. * Secondary aims are to assess its acceptability, to validate the CAT version, and to provide estimates of QoL across different European countries. The EUonQoL-Kit will be administered to a sample of cancer patients and survivors from 46 European cancer centres. The sample will include patients in active treatment (group A), survivors (group B), and patients in Palliative Care (group C). Each centre will recruit 100 patients (40 from group A, 30 from group B, 30 from group C), for an overall sample size of 4,600 patients (at least 4,000 patients are assumed to be enrolled, due to an expected lower recruitment rate of 10-15%). Three sub-samples of patients (each corresponding to 10% of the total sample for each centre) will fill in an additional questionnaire: * EORTC QLQ-C30, to test concurrent validity. * Live-CAT version, to test the feasibility of such implementation. * EUonQoL-Kit, 2-7 days after the first completion, to assess test-retest reliability. '''Sponsor''': Fondazione IRCCS Istituto Nazionale dei Tumori, Milano '''Intervention''': Administration of the EUonQoL-Kit - Active Treatment questionnaire '''Start Date''': 2024-04-01 '''Last Updated''': 2023-07-19 '''Number of Patients''': 4000 '''Recruitment Status''': NOT_YET_RECRUITING '''Condition''': Cancer '''NCTID''': NCT04210115 '''Title''': Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) '''Study Summary''': The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in: * participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 * participants whose tumors express PD-L1 CPS ≥1 * all participants The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to: * EFS in participants whose tumors express PD-L1 CPS ≥10 * EFS in participants whose tumors express PD-L1 CPS ≥1 * EFS in all participants * OS in participants whose tumors express PD-L1 CPS ≥10 * OS in participants whose tumors express PD-L1 CPS ≥1 * OS in all participants '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': pembrolizumab '''Start Date''': 2020-02-28 '''Last Updated''': 2023-11-27 '''Number of Patients''': 700 '''Recruitment Status''': RECRUITING '''Condition''': Esophageal Squamous Cell Carcinoma (ESCC) '''NCTID''': NCT03937154 '''Title''': Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer '''Study Summary''': To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy '''Sponsor''': Amgen '''Intervention''': Romiplostim '''Start Date''': 2020-02-26 '''Last Updated''': 2023-11-27 '''Number of Patients''': 162 '''Recruitment Status''': RECRUITING '''Condition''': Chemotherapy-induced Thrombocytopenia '''NCTID''': NCT00949650 '''Title''': BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation '''Study Summary''': This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients. '''Sponsor''': Boehringer Ingelheim '''Intervention''': Pemetrexed '''Start Date''': 2009-08-14 '''Last Updated''': 2018-04-06 '''Number of Patients''': 345 '''Recruitment Status''': COMPLETED '''Condition''': Carcinoma, Non-Small-Cell Lung '''NCTID''': NCT05429268 '''Title''': Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) '''Study Summary''': The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). '''Sponsor''': Incyte Corporation '''Intervention''': Tafasitamab '''Start Date''': 2022-12-23 '''Last Updated''': 2023-11-24 '''Number of Patients''': 81 '''Recruitment Status''': RECRUITING '''Condition''': Large B-Cell Lymphoma '''NCTID''': NCT00245154 '''Title''': Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer '''Study Summary''': RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving paclitaxel and carboplatin together with AZD2171 may kill more tumor cells. It is not yet known whether giving paclitaxel and carboplatin together with AZD2171 is more effective than giving paclitaxel and carboplatin together with a placebo in treating non-small cell lung cancer. PURPOSE: This randomized phase II/III trial is studying how well giving paclitaxel and carboplatin together with cediranib maleate works and compares it to giving paclitaxel and carboplatin together with placebo in treating patients with stage III or stage IV non-small cell lung cancer. '''Sponsor''': NCIC Clinical Trials Group '''Intervention''': carboplatin '''Start Date''': 2005-11-03 '''Last Updated''': 2023-08-04 '''Number of Patients''': 296 '''Recruitment Status''': COMPLETED '''Condition''': Lung Cancer '''NCTID''': NCT03815643 '''Title''': Avelumab Program Rollover Study '''Study Summary''': The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study. '''Sponsor''': EMD Serono Research & Development Institute, Inc. '''Intervention''': Avelumab '''Start Date''': 2019-03-22 '''Last Updated''': 2023-11-07 '''Number of Patients''': 161 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Solid Tumors '''NCTID''': NCT04428151 '''Title''': Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) '''Study Summary''': This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and a programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor. The primary hypothesis is that lenvatinib + pembrolizumab is superior to SOC chemotherapy with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Lenvatinib '''Start Date''': 2020-08-06 '''Last Updated''': 2023-11-24 '''Number of Patients''': 400 '''Recruitment Status''': RECRUITING '''Condition''': Squamous Cell Carcinoma of Head and Neck '''NCTID''': NCT00373425 '''Title''': A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors '''Study Summary''': This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients. '''Sponsor''': OSI Pharmaceuticals '''Intervention''': Erlotinib '''Start Date''': 2006-09 '''Last Updated''': 2015-09-17 '''Number of Patients''': 1252 '''Recruitment Status''': COMPLETED '''Condition''': Non-small Cell Lung Cancer '''NCTID''': NCT01543451 '''Title''': Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea '''Study Summary''': The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI regimen) in comparison to placebo. '''Sponsor''': Helsinn Healthcare SA '''Intervention''': Elsiglutide '''Start Date''': 2012-02 '''Last Updated''': 2014-03-26 '''Number of Patients''': 138 '''Recruitment Status''': COMPLETED '''Condition''': Diarrhea '''NCTID''': NCT03600883 '''Title''': A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) '''Study Summary''': Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors. '''Sponsor''': Amgen '''Intervention''': sotorasib '''Start Date''': 2018-08-27 '''Last Updated''': 2023-10-25 '''Number of Patients''': 713 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': KRAS p.G12C Mutant Advanced Solid Tumors '''NCTID''': NCT01121549 '''Title''': A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer '''Study Summary''': The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen, who either continued the same treatment or switched to Aromasin® for a total treatment period of 5 years. Only 65 Romanian patients were enrolled in the IES study. It would therefore appear to be essential to evaluate and confirm the tolerability of Aromasin® and the ways in which it is used on a broader sample of patients and under the standard conditions of use as stipulated in the MA. This Non-Interventional study was designed to address these issues. '''Sponsor''': Pfizer '''Intervention''': Aromasin '''Start Date''': 2010-02 '''Last Updated''': 2014-01-22 '''Number of Patients''': 378 '''Recruitment Status''': TERMINATED '''Condition''': Invasive Early Breast Cancer '''NCTID''': NCT03662126 '''Title''': KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment '''Study Summary''': This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT (Arm 2). The BAT administered will be determined by the treating physician, with the option to “cross-over” to KRT-232 treatment after 6 months of BAT or if the disease worsens at any time. '''Sponsor''': Kartos Therapeutics, Inc. '''Intervention''': KRT-232 '''Start Date''': 2019-01-15 '''Last Updated''': 2023-04-28 '''Number of Patients''': 385 '''Recruitment Status''': RECRUITING '''Condition''': Primary Myelofibrosis (PMF) '''NCTID''': NCT03859427 '''Title''': A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma '''Study Summary''': Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy. '''Sponsor''': Amgen '''Intervention''': Carfilzomib '''Start Date''': 2019-05-08 '''Last Updated''': 2023-10-27 '''Number of Patients''': 454 '''Recruitment Status''': COMPLETED '''Condition''': Relapsed or Refractory Multiple Myeloma '''NCTID''': NCT02684006 '''Title''': A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) '''Study Summary''': This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma '''Sponsor''': Pfizer '''Intervention''': Avelumab (MSB0010718C) '''Start Date''': 2016-03-23 '''Last Updated''': 2023-11-09 '''Number of Patients''': 888 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Renal Cell Cancer '''NCTID''': NCT00479752 '''Title''': Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer '''Study Summary''': To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly. '''Sponsor''': Central European Cooperative Oncology Group '''Intervention''': FOLFOX4 (Oxaliplatin), Cetuximab '''Start Date''': 2008-01 '''Last Updated''': 2016-02-18 '''Number of Patients''': 151 '''Recruitment Status''': COMPLETED '''Condition''': Colorectal Cancer '''NCTID''': NCT01818752 '''Title''': Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma '''Study Summary''': The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP). '''Sponsor''': Amgen '''Intervention''': Carfilzomib '''Start Date''': 2013-07-08 '''Last Updated''': 2019-08-26 '''Number of Patients''': 955 '''Recruitment Status''': COMPLETED '''Condition''': Multiple Myeloma '''NCTID''': NCT01949805 '''Title''': Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera '''Study Summary''': Phase III study to compare the efficacy and safety of the novel monopegylated interferon alpha 2b AOP2014 versus Hydroxyurea (the current licensed therapy for this disease). One year treatment of patients with polycythemia vera. Objective is to demonstrate non-inferiority of AOP2014 vs. HU in terms of disease response rate in both HU naïve and currently treated patients, diagnosed with Polycythemia Vera. Response is measured as normalisation of key lab parameters as well as normalized spleen size. '''Sponsor''': AOP Orphan Pharmaceuticals AG '''Intervention''': Peg-P-IFN-alpha-2b (AOP2014) '''Start Date''': 2013-09 '''Last Updated''': 2016-11-28 '''Number of Patients''': 257 '''Recruitment Status''': COMPLETED '''Condition''': Polycythemia Vera '''NCTID''': NCT03498716 '''Title''': A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer '''Study Summary''': This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator’s choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator’s choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer) '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2018-08-02 '''Last Updated''': 2023-09-15 '''Number of Patients''': 2203 '''Recruitment Status''': COMPLETED '''Condition''': Triple Negative Breast Cancer '''NCTID''': NCT03768063 '''Title''': A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study '''Study Summary''': This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2019-02-28 '''Last Updated''': 2023-11-09 '''Number of Patients''': 1000 '''Recruitment Status''': RECRUITING '''Condition''': Cancer '''NCTID''': NCT02928406 '''Title''': A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract '''Study Summary''': This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2016-11-30 '''Last Updated''': 2022-12-22 '''Number of Patients''': 1005 '''Recruitment Status''': COMPLETED '''Condition''': Urinary Tract Cancer '''NCTID''': NCT04811027 '''Title''': Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC '''Study Summary''': Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with PD-L1 positive (CPS ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors. '''Sponsor''': Immutep S.A.S. '''Intervention''': Eftilagimod alpha '''Start Date''': 2021-08-27 '''Last Updated''': 2023-11-13 '''Number of Patients''': 171 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': HNSCC '''NCTID''': NCT00943826 '''Title''': A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma '''Study Summary''': This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of care alone. Participants were randomly assigned to either the bevacizumab (10 milligrams per kilogram (mg/kg) intravenously <math display="block">IV</math> once every 2 week <math display="block">q2w</math>) or the placebo arm, in combination with radiation therapy (total dose 60 Gray <math display="block">Gy</math>, administered as 2 Gy fractions, 5 days/week) plus temozolomide (75 milligrams per meter squared <math display="block">mg/m\^2</math> oral administration <math display="block">po</math> daily) for 6 weeks. After a 4 week treatment break, participants continued to receive bevacizumab (10 mg/kg IV q2w) or placebo, plus temozolomide (150-200 mg/m^2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of maintenance treatment or until disease progression or unacceptable toxicity, whichever occured first. Following the maintenance phase, bevacizumab (15 mg/kg iv every 3 weeks <math display="block">q3w</math>) or placebo monotherapy continued. The time on study treatment was until disease progression. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Bevacizumab '''Start Date''': 2009-06-29 '''Last Updated''': 2017-09-25 '''Number of Patients''': 921 '''Recruitment Status''': COMPLETED '''Condition''': Glioblastoma '''NCTID''': NCT04994717 '''Title''': Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia '''Study Summary''': The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy. '''Sponsor''': Amgen '''Intervention''': Blinatumomab '''Start Date''': 2021-11-02 '''Last Updated''': 2023-11-18 '''Number of Patients''': 287 '''Recruitment Status''': RECRUITING '''Condition''': Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) '''NCTID''': NCT05249426 '''Title''': A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer '''Study Summary''': This study is open to adults with head and neck cancer or liver cancer. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether combining different medicines make tumours shrink in people with head and neck cancer or liver cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 765063 and ezabenlimab may help the immune system fight cancer (checkpoint inhibitors). Cetuximab blocks growth signals and may prevent the tumour from growing. BI 836880 blocks the formation of new blood vessels that the tumour needs to grow. All participants get BI 765063 and ezabenlimab. One group gets no additional medicine. The other groups get either BI 836880, cetuximab, or chemotherapy. BI 765063, ezabenlimab, and BI 836880 are given as infusions into veins every 3 weeks. Cetuximab is given as an infusion every 1 or 2 weeks. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors monitor the size of the tumour. The doctors also regularly check participants’ health and take note of any unwanted effects. '''Sponsor''': Boehringer Ingelheim '''Intervention''': BI 765063 '''Start Date''': 2022-02-25 '''Last Updated''': 2023-11-28 '''Number of Patients''': 45 '''Recruitment Status''': RECRUITING '''Condition''': Head and Neck Squamous Cell Carcinoma (HNSCC) '''NCTID''': NCT01663727 '''Title''': Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer '''Study Summary''': This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or placebo (10 mg/kg) will be administered by IV infusion on Days 1 and 15 of each 28-day cycle. Patients will be treated until disease progression, unacceptable toxicity or death from any cause occurs. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Bevacizumab [Avastin] '''Start Date''': 2012-08-27 '''Last Updated''': 2019-01-22 '''Number of Patients''': 481 '''Recruitment Status''': COMPLETED '''Condition''': Metastatic Breast Cancer '''NCTID''': NCT04624204 '''Title''': Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) '''Study Summary''': The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). Hypothesis (H1): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H2): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H3): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to OS. Hypothesis (H4): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab is superior to concurrent chemoradiation therapy alone with respect to OS. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab 200 mg '''Start Date''': 2020-12-08 '''Last Updated''': 2023-11-28 '''Number of Patients''': 672 '''Recruitment Status''': RECRUITING '''Condition''': Small Cell Lung Cancer '''NCTID''': NCT02213263 '''Title''': A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) '''Study Summary''': This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU. '''Sponsor''': Pfizer '''Intervention''': PF-05280586 '''Start Date''': 2014-09-30 '''Last Updated''': 2019-06-20 '''Number of Patients''': 394 '''Recruitment Status''': COMPLETED '''Condition''': Follicular Lymphoma '''NCTID''': NCT02566993 '''Title''': Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer '''Study Summary''': Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line. '''Sponsor''': PharmaMar '''Intervention''': Lurbinectedin (PM01183) '''Start Date''': 2016-08-30 '''Last Updated''': 2021-10-28 '''Number of Patients''': 613 '''Recruitment Status''': COMPLETED '''Condition''': Small-cell Lung Cancer '''NCTID''': NCT00465491 '''Title''': Study of Picoplatin Efficacy After Relapse '''Study Summary''': Picoplatin is a new type of platinum drug that has been investigated in several clinical trials, and may provide an improved safety profile over current treatment options. This study is designed to compare the efficacy and safety of picoplatin plus Best Supportive Care (BSC) with BSC alone. Best Supportive Care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side-effects of anti-cancer treatments. '''Sponsor''': Poniard Pharmaceuticals '''Intervention''': picoplatin '''Start Date''': 2007-04 '''Last Updated''': 2009-04-14 '''Number of Patients''': 399 '''Recruitment Status''': UNKNOWN '''Condition''': Small Cell Lung Cancer '''NCTID''': NCT03151408 '''Title''': An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia '''Study Summary''': This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic leukemia and cytogenetic low-risk AML, who are unfit to receive intensive remission induction chemotherapy due to age ≥ 75 years or comorbidities. Patients will be randomized in a 1:1 ratio to one of two groups: Group A (experimental group) to receive pracinostat plus AZA and Group B (control group) to receive placebo plus AZA. Randomization will be stratified by cytogenetic risk category (intermediate vs. unfavorable-risk, according to SWOG Cytogenetic Risk Category Definitions) and ECOG performance status (0-1 vs. 2). Treatments will be administered based on 28-day cycles, with pracinostat/placebo administered orally once every other day, 3 times a week for 3 weeks, followed by one week of no treatment and AZA administered for 7 days of each cycle. Study treatment should continue until there is documented disease progression, relapse from complete remission (CR), or non-manageable toxicity. A minimum of 6 cycles may be required to achieve a complete remission. Once permanently discontinued from study treatment, patients will enter the Long-term Follow-up phase of the study and will be followed for assessment of disease progression, if applicable, and survival every 3 months (±1 month) until death. The end of this study is defined when 390 events (deaths) have occurred and the study is unblinded for final overall survival analysis. Patients who are receiving study treatment at the end of the study may have the opportunity to continue to receive the study drugs to which they were randomized to (Post- Study Observation Period), until the Sponsor informs the Investigators of the appropriate course of action based on the study results. The Post-Study Observation Period is defined as the period starting from the end of the study for a maximum of 12 months. '''Sponsor''': Helsinn Healthcare SA '''Intervention''': Pracinostat '''Start Date''': 2017-06-23 '''Last Updated''': 2022-03-10 '''Number of Patients''': 406 '''Recruitment Status''': TERMINATED '''Condition''': Acute Myeloid Leukemia '''NCTID''': NCT01363479 '''Title''': An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting '''Study Summary''': PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that oral palonosetron 0.50 mg is as effective as (non-inferior to) palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy. '''Sponsor''': Helsinn Healthcare SA '''Intervention''': Oral palonosetron '''Start Date''': 2011-07 '''Last Updated''': 2021-09-22 '''Number of Patients''': 743 '''Recruitment Status''': COMPLETED '''Condition''': Chemotherapy-Induced Nausea and Vomiting '''NCTID''': NCT01147939 '''Title''': Study of Elacytarabine Versus Investigator’s Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) '''Study Summary''': The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator’s choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML). '''Sponsor''': Clavis Pharma '''Intervention''': Elacytarabine '''Start Date''': 2010-06 '''Last Updated''': 2013-09-27 '''Number of Patients''': 381 '''Recruitment Status''': COMPLETED '''Condition''': Acute Myeloid Leukemia (AML) '''NCTID''': NCT03416179 '''Title''': A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia '''Study Summary''': Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population). '''Sponsor''': Pfizer '''Intervention''': glasdegib '''Start Date''': 2018-04-20 '''Last Updated''': 2023-04-21 '''Number of Patients''': 730 '''Recruitment Status''': COMPLETED '''Condition''': Leukemia, Myeloid, Acute '''NCTID''': NCT00523159 '''Title''': IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease '''Study Summary''': This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma. Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination. '''Sponsor''': Immatics Biotechnologies GmbH '''Intervention''': Endoxana, IMA901, Leukine '''Start Date''': 2007-05 '''Last Updated''': 2012-07-10 '''Number of Patients''': 68 '''Recruitment Status''': COMPLETED '''Condition''': Renal Cell Carcinoma '''NCTID''': NCT02273375 '''Title''': Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC '''Study Summary''': The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer. '''Sponsor''': Canadian Cancer Trials Group '''Intervention''': MEDI4736 '''Start Date''': 2015-02-24 '''Last Updated''': 2023-10-27 '''Number of Patients''': 1415 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Non-Small Cell Lung Cancer '''NCTID''': NCT00878709 '''Title''': Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer '''Study Summary''': The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab. '''Sponsor''': Puma Biotechnology, Inc. '''Intervention''': neratinib '''Start Date''': 2009-07-09 '''Last Updated''': 2021-06-11 '''Number of Patients''': 2840 '''Recruitment Status''': COMPLETED '''Condition''': Breast Cancer '''NCTID''': NCT03833167 '''Title''': Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) '''Study Summary''': This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab 400 mg '''Start Date''': 2019-04-01 '''Last Updated''': 2023-11-27 '''Number of Patients''': 430 '''Recruitment Status''': RECRUITING '''Condition''': Carcinoma, Squamous Cell '''NCTID''': NCT02786329 '''Title''': Anesthesia and Postoperative Outcome in Colorectal Cancer Patients '''Study Summary''': Study aims to compare the influence of TIVA and sevoflurane anesthesia with or without lidocaine on postoperative short and long term outcome in patients with colorectal cancer undergoing surgery. As short term endpoints postoperative pain and opioid consumption, resumption of bowel function, PONV, LOS will be registered. Long term outcome parameters include: the incidence of chronic pain, 1 and 5 years cancer recurrences incidence and mortality. '''Sponsor''': Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor '''Intervention''': TIVA+lidocaine '''Start Date''': 2016-06 '''Last Updated''': 2022-01-20 '''Number of Patients''': 450 '''Recruitment Status''': RECRUITING '''Condition''': Colorectal Cancer '''NCTID''': NCT00805194 '''Title''': LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer '''Study Summary''': The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis. '''Sponsor''': Boehringer Ingelheim '''Intervention''': placebo plus docetaxel '''Start Date''': 2008-12-03 '''Last Updated''': 2018-12-05 '''Number of Patients''': 1314 '''Recruitment Status''': COMPLETED '''Condition''': Carcinoma, Non-Small-Cell Lung '''NCTID''': NCT00785122 '''Title''': IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101) '''Study Summary''': This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients with advanced CRC to warrant further development. Secondary objectives of this study are investigation of immunological parameters and additional effectiveness endpoints. Furthermore, safety, immunological parameters and effectiveness of IMA910 as single agent with GM-CSF in combination with imiquimod following pre-treatment with low-dose cyclophosphamide will be investigated in a 2nd cohort of patients. The regular study duration for individual patients in the 1st and 2nd cohort comprises regularly 18-42 days of screening (excluding HLA-typing), 33 weeks of treatment (16 vaccinations) and 4 weeks follow-up. Thus, the period between start of screening and end of trial is about 10 months per patient. Patients will be followed for response to subsequent treatments (chemotherapies with or without targeted agents) and survival every 2 months after EOS visit until death. Patients in the 1st and 2nd cohort will be withdrawn from study treatment once a progress according to RECIST is noted. An enrolment plan for the first 6 patients included into the 1st cohort will be part of this study to ensure maximum safety of the study participants. The enrollment of the first 6 patients into the 2nd cohort will also follow an enrolment plan to ensure maximum safety. '''Sponsor''': Immatics Biotechnologies GmbH '''Intervention''': Endoxana, Leukine, IMA910 '''Start Date''': 2008-06 '''Last Updated''': 2013-05-16 '''Number of Patients''': 92 '''Recruitment Status''': COMPLETED '''Condition''': Colorectal Carcinoma '''NCTID''': NCT00036647 '''Title''': OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer '''Study Summary''': The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA). '''Sponsor''': OSI Pharmaceuticals '''Intervention''': Tarceva (erlotinib HCl, OSI-774 ) '''Start Date''': 2001-11-01 '''Last Updated''': 2018-01-10 '''Number of Patients''': 731 '''Recruitment Status''': COMPLETED '''Condition''': Carcinoma, Non-small-cell Lung '''NCTID''': NCT04586231 '''Title''': A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) '''Study Summary''': This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Belzutifan '''Start Date''': 2021-02-25 '''Last Updated''': 2023-08-14 '''Number of Patients''': 708 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Carcinoma, Renal Cell '''NCTID''': NCT04953910 '''Title''': Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment '''Study Summary''': This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 mg and cedazuridine 100 mg in cancer participants with moderate and severe hepatic impairment and cancer participants with normal hepatic function as control subjects. Participants with severe hepatic impairment will be enrolled only after the safety evaluation of at least 6 participants with moderate hepatic impairment has been determined and supports the enrollment of participants with severe hepatic impairment. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration is approximately up to 8 weeks. '''Sponsor''': Astex Pharmaceuticals, Inc. '''Intervention''': ASTX727 '''Start Date''': 2022-12-23 '''Last Updated''': 2023-09-01 '''Number of Patients''': 27 '''Recruitment Status''': RECRUITING '''Condition''': Acute Myeloid Leukemia '''NCTID''': NCT02625610 '''Title''': Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) '''Study Summary''': The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy. '''Sponsor''': EMD Serono Research & Development Institute, Inc. '''Intervention''': Avelumab '''Start Date''': 2015-12-24 '''Last Updated''': 2022-06-09 '''Number of Patients''': 499 '''Recruitment Status''': COMPLETED '''Condition''': Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction '''NCTID''': NCT03158688 '''Title''': Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. '''Study Summary''': Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies. '''Sponsor''': Amgen '''Intervention''': Dexamethasone '''Start Date''': 2017-06-13 '''Last Updated''': 2023-05-12 '''Number of Patients''': 466 '''Recruitment Status''': COMPLETED '''Condition''': Relapsed Multiple Myeloma '''NCTID''': NCT03743064 '''Title''': A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) '''Study Summary''': Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at least 1 hour before their first meal of the day '''Sponsor''': Helsinn Healthcare SA '''Intervention''': anamorelin HCl '''Start Date''': 2018-12-18 '''Last Updated''': 2023-04-06 '''Number of Patients''': 318 '''Recruitment Status''': COMPLETED '''Condition''': Cachexia; Cancer '''NCTID''': NCT01860638 '''Title''': A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma '''Study Summary''': This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line <math display="block">2L</math> treatment) and SOC (in 3rd-line <math display="block">3L</math> and subsequent lines of treatment) following first-line disease progression (PD1) in participants with newly diagnosed glioblastoma. All enrolled participants will receive 1L treatment with radiotherapy, temozolomide, and bevacizumab. At PD1, eligible participants will be randomized (1:1) to receive 2L treatment with either bevacizumab plus lomustine or placebo plus lomustine. After second-line disease progression (PD2), participants will receive 3L treatment and will continue blinded bevacizumab or placebo with the addition of an SOC agent. Following third-line disease progression (PD3), participants will receive subsequent lines of treatment and will either continue blinded bevacizumab or placebo (at the discretion of the investigator), or switch to open-label bevacizumab (at the choice of the participant). '''Sponsor''': Hoffmann-La Roche '''Intervention''': Bevacizumab '''Start Date''': 2013-08-19 '''Last Updated''': 2018-04-30 '''Number of Patients''': 296 '''Recruitment Status''': COMPLETED '''Condition''': Glioblastoma '''NCTID''': NCT04764188 '''Title''': An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib '''Study Summary''': This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Alectinib '''Start Date''': 2021-05-10 '''Last Updated''': 2023-11-08 '''Number of Patients''': 800 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': NSCLC '''NCTID''': NCT04873362 '''Title''': A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy '''Study Summary''': This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2021-05-04 '''Last Updated''': 2023-11-13 '''Number of Patients''': 1700 '''Recruitment Status''': RECRUITING '''Condition''': Breast Cancer '''NCTID''': NCT04205812 '''Title''': Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer '''Study Summary''': The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC). '''Sponsor''': Incyte Corporation '''Intervention''': Retifanlimab '''Start Date''': 2020-09-27 '''Last Updated''': 2023-10-26 '''Number of Patients''': 583 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Metastatic Squamous Non-Small Cell Lung Cancer '''NCTID''': NCT04123366 '''Title''': Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) '''Study Summary''': The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Olaparib '''Start Date''': 2019-11-18 '''Last Updated''': 2023-06-15 '''Number of Patients''': 300 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Solid Tumors '''NCTID''': NCT05325866 '''Title''': A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression '''Study Summary''': The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity. '''Sponsor''': Amgen '''Intervention''': Bemarituzumab '''Start Date''': 2022-09-23 '''Last Updated''': 2023-11-09 '''Number of Patients''': 303 '''Recruitment Status''': RECRUITING '''Condition''': Solid Tumors '''NCTID''': NCT02303821 '''Title''': Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia '''Study Summary''': The purpose of Phase 1b of this study is to: * Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL). * Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy. The purpose of Phase 2 of this study is to compare the rate of complete remission (CR) of carfilzomib in combination with vincristine, dexamethasone, PEG asparaginase, daunorubicin (VXLD) at the end of induction therapy to an appropriate external control. '''Sponsor''': Amgen '''Intervention''': Carfilzomib '''Start Date''': 2015-02-16 '''Last Updated''': 2023-10-23 '''Number of Patients''': 130 '''Recruitment Status''': RECRUITING '''Condition''': Acute Lymphoblastic Leukemia (ALL) '''NCTID''': NCT03498521 '''Title''': A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site '''Study Summary''': This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Alectinib '''Start Date''': 2018-07-10 '''Last Updated''': 2023-11-18 '''Number of Patients''': 790 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Cancer of Unknown Primary Site '''NCTID''': NCT04622319 '''Title''': A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) '''Study Summary''': Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy. '''Sponsor''': Daiichi Sankyo, Inc. '''Intervention''': DS-8201a '''Start Date''': 2020-12-04 '''Last Updated''': 2023-11-07 '''Number of Patients''': 1600 '''Recruitment Status''': RECRUITING '''Condition''': HER2-Positive Primary Breast Cancer '''NCTID''': NCT05501886 '''Title''': Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) '''Study Summary''': This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. '''Sponsor''': Celcuity, Inc. '''Intervention''': Gedatolisib '''Start Date''': 2022-09-30 '''Last Updated''': 2023-08-01 '''Number of Patients''': 701 '''Recruitment Status''': RECRUITING '''Condition''': Breast Cancer '''NCTID''': NCT04241185 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) '''Study Summary''': This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2020-05-19 '''Last Updated''': 2023-11-27 '''Number of Patients''': 636 '''Recruitment Status''': RECRUITING '''Condition''': Urinary Bladder Neoplasms '''NCTID''': NCT03191786 '''Title''': A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy '''Study Summary''': This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 <math display="block">anti-PD-L1</math> antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group <math display="block">ECOG</math> performance status of 2-3). '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody '''Start Date''': 2017-09-11 '''Last Updated''': 2023-11-07 '''Number of Patients''': 453 '''Recruitment Status''': COMPLETED '''Condition''': Non-Small Cell Lung Cancer '''NCTID''': NCT02216786 '''Title''': A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer '''Study Summary''': This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer, whose disease relapsed during treatment with (or within 12 months after discontinuation of) an AI in the adjuvant setting or progressed during treatment with an AI in the metastatic setting. Patients will be randomised (2:3:3:2) to one of the four treatment arms: * Fulvestrant * Fulvestrant + AZD2014 (continuous daily schedule) * Fulvestrant + AZD2014 (intermittent schedule - 2 days on, 5 days off) * Fulvestrant + everolimus Randomization will be stratified by the following criteria: * Measurable disease (vs. non-measurable). * Sensitivity to prior endocrine therapy (sensitive versus resistant) '''Sponsor''': Queen Mary University of London '''Intervention''': AZD2014 '''Start Date''': 2014-01 '''Last Updated''': 2020-02-25 '''Number of Patients''': 333 '''Recruitment Status''': UNKNOWN '''Condition''': Estrogen Receptor Positive Breast Cancer '''NCTID''': NCT00088530 '''Title''': BBR 2778 for Relapsed, Aggressive Non-Hodgkin’s Lymphoma (NHL) '''Study Summary''': BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore). '''Sponsor''': CTI BioPharma '''Intervention''': pixantrone, cyclophosphamide, vincristine, rituximab, prednisone '''Start Date''': 2004-07 '''Last Updated''': 2020-02-05 '''Number of Patients''': 140 '''Recruitment Status''': COMPLETED '''Condition''': Lymphoma, Non-Hodgkin '''NCTID''': NCT00707304 '''Title''': Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer '''Study Summary''': The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens. '''Sponsor''': Agennix '''Intervention''': Talactoferrin '''Start Date''': 2008-11 '''Last Updated''': 2012-08-21 '''Number of Patients''': 742 '''Recruitment Status''': COMPLETED '''Condition''': Non Small Cell Lung Cancer '''NCTID''': NCT05111626 '''Title''': Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer '''Study Summary''': The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival. '''Sponsor''': Amgen '''Intervention''': Bemarituzumab '''Start Date''': 2022-03-14 '''Last Updated''': 2023-11-27 '''Number of Patients''': 528 '''Recruitment Status''': RECRUITING '''Condition''': Gastric Cancer '''NCTID''': NCT04956692 '''Title''': Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) '''Study Summary''': The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state. Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab SC '''Start Date''': 2021-08-05 '''Last Updated''': 2023-09-05 '''Number of Patients''': 531 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Non-Small Cell Lung Cancer '''NCTID''': NCT02629692 '''Title''': Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies '''Study Summary''': Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML '''Sponsor''': Sun Pharma Advanced Research Company Limited '''Intervention''': Vodobatinib (K0706) capsules '''Start Date''': 2017-04-25 '''Last Updated''': 2023-10-27 '''Number of Patients''': 122 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Healthy (For Part A) '''NCTID''': NCT02557035 '''Title''': An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting '''Study Summary''': PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that infused IV palonosetron 0.25 mg is as effective as (non-inferior to) injected palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy '''Sponsor''': Helsinn Healthcare SA '''Intervention''': Palonosetron '''Start Date''': 2015-10 '''Last Updated''': 2018-06-20 '''Number of Patients''': 441 '''Recruitment Status''': COMPLETED '''Condition''': Chemotherapy-Induced Nausea and Vomiting '''NCTID''': NCT03148418 '''Title''': A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) '''Study Summary''': This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2017-09-20 '''Last Updated''': 2023-11-18 '''Number of Patients''': 382 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Cancer '''NCTID''': NCT03165734 '''Title''': A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis '''Study Summary''': This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician’s choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib '''Sponsor''': CTI BioPharma '''Intervention''': Pacritinib '''Start Date''': 2017-06-26 '''Last Updated''': 2023-11-13 '''Number of Patients''': 399 '''Recruitment Status''': RECRUITING '''Condition''': Primary Myelofibrosis '''NCTID''': NCT00522834 '''Title''': Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma '''Study Summary''': "Elesclomol (STA-4783), N-malonyl-bis (N’-methyl-N’-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. Subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. Eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either STA-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone. One treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. Cycles will be repeated every 4 weeks until disease progression. Tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the Investigator suspects progression has occurred based on clinical signs and symptoms. " '''Sponsor''': Synta Pharmaceuticals Corp. '''Intervention''': Elesclomol (STA-4783) '''Start Date''': 2007-08 '''Last Updated''': 2014-03-04 '''Number of Patients''': 630 '''Recruitment Status''': TERMINATED '''Condition''': Melanoma '''NCTID''': NCT04380636 '''Title''': Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) '''Study Summary''': The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are: # Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS) # Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS and OS '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2020-07-06 '''Last Updated''': 2023-11-07 '''Number of Patients''': 870 '''Recruitment Status''': RECRUITING '''Condition''': Lung Neoplasms '''NCTID''': NCT05023980 '''Title''': A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) '''Study Summary''': The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years. '''Sponsor''': Loxo Oncology, Inc. '''Intervention''': Pirtobrutinib '''Start Date''': 2021-09-23 '''Last Updated''': 2023-07-11 '''Number of Patients''': 250 '''Recruitment Status''': RECRUITING '''Condition''': Chronic Lymphocytic Leukemia '''NCTID''': NCT02771795 '''Title''': A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC '''Study Summary''': A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC '''Sponsor''': Samsung Bioepis Co., Ltd. '''Intervention''': Herceptin (trastuzumab) '''Start Date''': 2016-04 '''Last Updated''': 2021-01-07 '''Number of Patients''': 549 '''Recruitment Status''': TERMINATED '''Condition''': Breast Neoplasms '''NCTID''': NCT04700124 '''Title''': Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) '''Study Summary''': The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy <math display="block">gemcitabine plus cisplatin</math> and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2021-04-21 '''Last Updated''': 2023-11-18 '''Number of Patients''': 784 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Muscle Invasive Bladder Cancer '''NCTID''': NCT05879757 '''Title''': Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency '''Study Summary''': In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic’s standard practice. The study’s main aim is to look into infusion parameters of HyQvia administration. '''Sponsor''': Takeda '''Intervention''': No Intervention '''Start Date''': 2023-10-17 '''Last Updated''': 2023-11-01 '''Number of Patients''': 100 '''Recruitment Status''': RECRUITING '''Condition''': Multiple Myeloma '''NCTID''': NCT01479244 '''Title''': Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence '''Study Summary''': Purpose of this trial: # To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF). # To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects. '''Sponsor''': Galena Biopharma, Inc. '''Intervention''': NeuVax™ vaccine '''Start Date''': 2011-11 '''Last Updated''': 2017-02-27 '''Number of Patients''': 758 '''Recruitment Status''': COMPLETED '''Condition''': Breast Cancer With Low to Intermediate HER2 Expression '''NCTID''': NCT06117774 '''Title''': Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) '''Study Summary''': The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS). '''Sponsor''': Amgen '''Intervention''': Tarlatamab '''Start Date''': 2024-01-27 '''Last Updated''': 2023-11-07 '''Number of Patients''': 400 '''Recruitment Status''': NOT_YET_RECRUITING '''Condition''': Limited Stage Small Cell Lung Cancer '''NCTID''': NCT04194944 '''Title''': A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer '''Study Summary''': The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib. '''Sponsor''': Loxo Oncology, Inc. '''Intervention''': Selpercatinib '''Start Date''': 2020-02-17 '''Last Updated''': 2023-10-30 '''Number of Patients''': 261 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Non-Small Cell Lung Cancer '''NCTID''': NCT00682981 '''Title''': A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) '''Study Summary''': The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen. '''Sponsor''': Gemin X '''Intervention''': Obatoclax '''Start Date''': 2008-05 '''Last Updated''': 2016-07-21 '''Number of Patients''': 218 '''Recruitment Status''': COMPLETED '''Condition''': Extensive-stage Small Cell Lung Cancer '''NCTID''': NCT02576574 '''Title''': Avelumab in First-line NSCLC (JAVELIN Lung 100) '''Study Summary''': The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors. '''Sponsor''': EMD Serono Research & Development Institute, Inc. '''Intervention''': Avelumab '''Start Date''': 2015-10-29 '''Last Updated''': 2023-11-07 '''Number of Patients''': 1214 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': First Line Non-Small Cell Lung Cancer '''NCTID''': NCT01989676 '''Title''': A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) '''Study Summary''': The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280014 in combination with paclitaxel versus trastuzumab sourced from the European Union (trastuzumab-EU) with paclitaxel in female patients with HER2-positive, metastatic breast cancer in the first-line treatment setting. The hypothesis to be tested in this study is that the efficacy (ORR) of PF-05280014 is similar to trastuzumab-EU. '''Sponsor''': Pfizer '''Intervention''': PF-05280014 '''Start Date''': 2014-02-24 '''Last Updated''': 2021-07-06 '''Number of Patients''': 707 '''Recruitment Status''': COMPLETED '''Condition''': Metastatic Breast Cancer '''NCTID''': NCT00088270 '''Title''': A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer '''Study Summary''': Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer. '''Sponsor''': OSI Pharmaceuticals '''Intervention''': OSI-7904L '''Start Date''': 2004-08 '''Last Updated''': 2006-02-22 '''Number of Patients''': 58 '''Recruitment Status''': COMPLETED '''Condition''': Locally Advanced or Metastatic Adenoca of the Biliary Tract '''NCTID''': NCT05382299 '''Title''': Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician’s Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer '''Study Summary''': The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician’s choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1. '''Sponsor''': Gilead Sciences '''Intervention''': Sacituzumab Govitecan-hziy '''Start Date''': 2022-07-20 '''Last Updated''': 2023-11-15 '''Number of Patients''': 540 '''Recruitment Status''': RECRUITING '''Condition''': Triple Negative Breast Cancer '''NCTID''': NCT05888844 '''Title''': A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma '''Study Summary''': This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma. '''Sponsor''': Incyte Corporation '''Intervention''': INCB099280 '''Start Date''': 2023-10-09 '''Last Updated''': 2023-11-24 '''Number of Patients''': 240 '''Recruitment Status''': RECRUITING '''Condition''': Cutaneous Squamous Cell Carcinoma '''NCTID''': NCT03088813 '''Title''': Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer '''Study Summary''': A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy The study was conducted in two parts: # Dose determination of irinotecan liposome injection # A randomized, efficacy study of irinotecan liposome injection versus topotecan '''Sponsor''': Ipsen '''Intervention''': Irinotecan liposome injection '''Start Date''': 2018-04-25 '''Last Updated''': 2023-10-17 '''Number of Patients''': 491 '''Recruitment Status''': COMPLETED '''Condition''': Small Cell Lung Cancer '''NCTID''': NCT03042611 '''Title''': A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer '''Study Summary''': The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC). '''Sponsor''': Elevar Therapeutics '''Intervention''': Rivoceranib '''Start Date''': 2017-03-14 '''Last Updated''': 2022-07-08 '''Number of Patients''': 460 '''Recruitment Status''': COMPLETED '''Condition''': Gastric Cancer <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> <span style="display:none">hasCancerType::C00-C97: All cancer types</span> <span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span> <span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span> <span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span> <span style="display:none">hasCancerType::C40-C41: Bone cancers</span> <span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span> <span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span> <span style="display:none">hasCancerType::C50: Breast cancer</span> <span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span> <span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> <span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span> <span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span> <span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span> <span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span> <span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span> <span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span> <span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span> <span style="display:none">hasCancerType::D10-D36: Benign tumour</span> <span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span> <span style="display:none">hasCancerType::unknown</span> <span style="display:none">isTrial</span>
Summary:
Please note that all contributions to Beacon may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Beacon:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Tools
What links here
Related changes
Special pages
Page information
